Priyanka Parajuli

Dr. Priyanka Parajuli

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Cody BarbariCody Barbari
Cody Barbari
TFTyler Fontaine
Tyler Fontaine
PPPriyanka Parajuli
Priyanka Parajuli
NLNarottam Lamichhane
Narottam Lamichhane
SJSilvia Jakubski
Silvia Jakubski
RDRahul Deshmukh
Rahul Deshmukh
The advent of novel immunotherapies in the treatment of cancers has dramatically changed the landscape of the oncology field. Recent developments in checkpoint inhibition therapies, tumor-infiltrating lymphocyte therapies, chimeric antigen receptor T cell therapies, and cancer vaccines have shown immense promise for significant advancements in cancer treatments. Immunotherapies act on distinct steps of immune response to augment the body’s natural ability to recognize, target, and destroy cancerous cells. Combination treatments with immunotherapies and other modalities intend to activate immune response, decrease immunosuppression, and target signaling and resistance pathways to offer a more durable, long-lasting treatment compared to traditional therapies and immunotherapies as monotherapies for cancers. This review aims to briefly describe the rationale, mechanisms of action, and clinical efficacy of common immunotherapies and highlight promising combination strategies currently approved or under clinical development. Additionally, we will discuss the benefits and limitations of these immunotherapy approaches as monotherapies as well as in combination with other treatments.

20 May 2020 in Medicines
Verified
Journal Article
Open access
PDF file
PPPriyanka Parajuli
Priyanka Parajuli
OLOdalys Estefania Lara-Garcia
Odalys Estefania Lara-Garcia
MRManjari Regmi
Manjari Regmi
WSWarren Skoza
Warren Skoza
MBMukul Bhattarai
Mukul Bhattarai
RRRobert Leonard Robinson
Robert Leonard Robinson
Background: The pharmacologic management of heart failure with preserved ejection fraction (HFpEF) involves far fewer options with demonstrated additional benefit. Therefore, we examined the effect of combination of multiple classes of HF medication in the 30-day hospital readmission in patients with HFpEF. Methods: All adult patients discharged with a diagnosis of HFpEF and a left ventricular ejection fraction (LVEF) of ≥ 50% reported during the admission or within the previous six months from our institution were retrospectively studied for a 30-day hospital readmission risk. Individual as well as combination drug therapy at the time of hospital discharge were evaluated using Pearson chi2 test and multivariate logistic regression. Results: The overall 30-day readmission rate in this HFpEF cohort of 445 discharges was 29%. Therapy with loop diuretics (p = 0.011), loop diuretics and angiotensin receptor blocker (p = 0.043) and loop diuretics and beta blockers (p = 0.049) were associated with a lower risk of 30-day hospital readmission. Multivariate logistic regression revealed only loop diuretics to be associated with a lower risk of hospital readmission in patients with HFpEF (OR 0.59; 95% CI, 0.39-0.90; p = 0.013). Conclusions: Our study revealed that loop diuretics at discharge decreases early readmission in patients with HFpEF. Further, our study highlights the implication of a lack of guidelines and treatment challenges in HFpEF patients and emphasizes the importance of a conservative approach in preventing early readmission in patients with HFpEF.

2 July 2019 in Cureus
Verified
Journal Article
Open access
PDF file
PPPriyanka Parajuli
Priyanka Parajuli
AIAbdisamad M. Ibrahim
Abdisamad M. Ibrahim
HSHarris H. Siddiqui
Harris H. Siddiqui
OGOdalys Estefania Lara Garcia
Odalys Estefania Lara Garcia
MRManjari Regmi
Manjari Regmi
Trimethoprim-sulfamethoxazole (TMP-SMX) is a bacteriostatic antimicrobial medication used for the treatment of a variety of infections and has many reported skin and hematologic side effects. Due to the easy availability and cost effectiveness, TMP-SMX is one of the medications commonly used for treatment of skin and soft tissue in patients with methicillin-resistant Staphylococcus aureus (MRSA) infection. One of the rare hematologic manifestations of TMP-SMX is pancytopenia, which is a reduction in all cell lines. In this case report, we are documenting a case of pancytopenia due to severe drug reaction to TMP-SMX in a 70-year-old female after two weeks of medication use. Upon initial stabilization she underwent a thorough workup and was subsequently diagnosed with severe drug-induced pancytopenia. Detailed history, early diagnosis, prompt discontinuation of the offending medication along with supportive care remain the mainstay of treatment in the management of TMP-SMX induced pancytopenia.

3 July 2020 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
PPPriyanka Parajuli
Priyanka Parajuli
MRManjari Regmi
Manjari Regmi
OLOdalys Estefania Lara-Garcia
Odalys Estefania Lara-Garcia
ILIsmael Abu Limon
Ismael Abu Limon
ADAlan Deckard
Alan Deckard
Synthetic Cannabinoids (SCB) are engineered chemical compounds that share a similar chemical structure with the active ingredient of marijuana, delta-9-tetrahydrocanabinol. Although the FDA has not approved the use of SCB without a prescription from a licensed health-care provider, the cost effectiveness and availability of SCB has made it a popular choice among recreational drug users. Manufacture of SCB as a street drug is not regulated. These SCB are highly potent chemicals that cause various severe toxicities. In this case report, we describe an adult who suffered from PRES after consuming K2, a synthetic cannabinoid.

26 September 2019 in Cureus
Verified
Journal Article
Open access
PDF file
MRManjari Regmi
Manjari Regmi
SCSarah-Grace Carbrey
Sarah-Grace Carbrey
PPPriyanka Parajuli
Priyanka Parajuli
OGOdalys Estefania Lara Garcia
Odalys Estefania Lara Garcia
MBMukul Bhattarai
Mukul Bhattarai
Constituting less than 25% of all renal artery dissections (RAD), isolated spontaneous renal artery dissection (SRAD) is a rare diagnosis that can cause subsequent renal infarction with impairment. The majority of SRAD cases are idiopathic. Management ranges from conservative, medical to endovascular, and surgical repair. We report a case of a young female on multiple medications who presented with SRAD. She presented with acute abdominal pain and was found to have isolated spontaneous renal artery dissection. The etiology of this patient’s isolated SRAD could possibly be pinned down to her multiple stimulant medications used after the major known causes were ruled out.